

5,000 to 50,000 u/ml of mucopolysaccharides when intended for sub-cutaneous injection or 5000 u/ml when intended for intravenous injection for perfusion.

79. A method for the preventive treatment and/or the treatment of thrombosis comprising the use of a composition according to claim <sup>76</sup> 77.

80. A mucopolysaccharide having heparinic constituents, which mucopolysaccharide has improved inhibition activity in vivo with respect to coagulation factor Xa (anti Xa) higher than that of heparin and which mucopolysaccharide has a USP titer of not more than about 9, an anti-Xa titer not less than about 100, an anti-Xa to USP ratio of titers over about 10 and a molecular weight in the range of about 4,000 to 10,000 and the pharmaceutically acceptable salts thereof.

81. The mucopolysaccharide of claim <sup>80</sup> 81 wherein the USP titer is less than 10, the anti-Xa titer in the range of about 135 to 161, the anti-Xa titer to USP titer ratio in the range of 13 to 16 and a molecular weight in the range of about 4,000 to 8,000. - -

#### R E M A R K S

The claims which have been substituted for claims 29-63 are defining the invention with even greater particularity and are drawn to products having a higher Yin-Wessler to USP titer ratio than the prior claims.


Attention of the Examiner is invited to claims 81 and 82 which are especially based on Table I, page 26 and drawn to the products of D, E, F, G and H.

The claims in the case are now 64 - 82.

The remarks submitted previously are incorporated herein by reference.

Favorable recommendation is respectfully requested.

Respectfully submitted,



---

GERARD J. WEISER, ESQ.  
Reg. No. 19,763  
Weiser, Stapler & Spivak, P.C.  
Attorneys for Applicants

WEISER, STAPLER & SPIVAK  
1510 Two Penn Center Plaza  
Philadelphia, PA 19102  
(215) 563-6600